Skip to content

Educational reference only. Not medical advice, diagnosis, or treatment, and not dosing, injection, or purchasing guidance.Medical disclaimer

FDA Category 2 and withdrawn nominations

This is a note about documents, not a complete legal opinion.

  • FDA says bulk substances nominated for the 503A or 503B bulks lists can be placed in Category 2 under interim policies when FDA identifies potential significant safety risks.
  • The Category 2 table opened for this draft includes, among other substances, GHRP-2 (injectable and nasal, 503B, added 29 September 2023), GHRP-6 (503B, same date), and ipamorelin acetate (503B, same date). The table also lists substances that are not peptides. This page does not copy every row.
  • A second table, “Bulk drug substances nominated but withdrawn,” says those substances were previously in Category 2 and were withdrawn by the nominators. Entries relevant to other pages on this wiki include BPC-157, CJC-1295, injectable GHK-Cu, melanotan II, MOTs-C, and thymosin beta-4 fragment (LKKTETQ), also called TB-500.
  • Withdrawal by a nominator is not, on this page, rewritten as a statement that compounding is lawful or unlawful. Read the FDA page and the statute before relying on a legal conclusion.

Dates of withdrawal are not stated because the opened page did not print a withdrawal date for those rows.

This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.

Page record

  • Type: Regulation
  • Domain: peptides
  • Evidence: Not rated
  • Status: reviewed
  • Last reviewed: 2026-11-20

Regulatory status: U.S. FDA interim categories for bulk substances nominated under sections 503A or 503B. Not a full statement of compounding law.

Sources

Referenced by

A link from another wiki page is not evidence. Facts should point at the sources above.